Abstract
Clinical trials of vaccines differ from those of drugs both practically and ethically. Influenza vaccine trials pose additional challenges which flow from the seasonality of the disease and vaccine programmes and the changeability of circulating strains and epidemic size. Serological correlates are widely used in evaluating influenza vaccines but interpreting such responses is also difficult. Development and testing of vaccines for deployment in an influenza pandemic combines all these obstacles with extreme unpredictability, enormous urgency and the need for very large numbers of doses. Advances in manufacturing technology, diagnostics, identification of stable protective antigens and epitopes, new adjuvants and improved understanding of indirect and downstream effects may help to alleviate these difficulties in the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grady C (2004) Ethics of vaccine research. Nat Immunol 5(5):465–468
Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. (2005) The Brighton Collaboration: creating a global standard for case definitions (and Guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI (eds) Advances in patient safety: from research to implementation. Concepts and methodology, vol. 2. Advances in patient safety. Rockville, MD
Heyse JF, Kuter BJ, Dallas MJ, Heaton P, Team RS (2008) Evaluating the safety of a rotavirus vaccine: the REST of the story. Clin Trials 5(2):131–139
Heikkinen T, Tsolia M, Finn A (2013) Vaccination of healthy children against seasonal influenza: a European perspective. Pediatr Infect Dis J 32(8):881–888
Wendler D (2010) The ethics of pediatric research. Oxford University Press, New York
Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G et al (2015) Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. Open Forum Infect Dis 2(2):ofv067
Laurie KL, Engelhardt OG, Wood J, Heath A, Katz JM, Peiris M et al (2015) International laboratory comparison of influenza microneutralization assays for a(H1N1)pdm09, a(H3N2), and a(H5N1) influenza viruses by CONSISE. Clin Vaccine Immunol 22(8):957–964
Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Drame M et al (2015) Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study. Vaccine 33(24):2800–2807
Pollard AJ, Reiner A, John T, Sheasby E, Snape M, Faust S et al (2009) Future of flu vaccines. Expediting clinical trials in a pandemic. BMJ 339:b4652
Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S et al (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340:c2649
Krammer F (2015) The quest for a universal flu vaccine: headless HA 2.0. Cell Host Microbe 18(4):395–397
Pollard AJ, Finn A, Curtis N (2017) Non-specific effects of vaccines: plausible and potentially important, but significance uncertain. Arch Dis Child 102(11):1077–1081
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Finn, A. (2018). Clinical Trials of Influenza Vaccines: Special Challenges. In: Yamauchi, Y. (eds) Influenza Virus. Methods in Molecular Biology, vol 1836. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8678-1_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8678-1_27
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8677-4
Online ISBN: 978-1-4939-8678-1
eBook Packages: Springer Protocols